About
Profile
At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
GILD
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Gilead Sciences Non-GAAP EPS of $1.72 misses by $0.04, revenue of $7.12B beats by $20M
- Gilead set to roll out Q4 results post-market Tuesday
- Gilead Sciences stock traded in the red for seventh straight session
- Earnings week ahead: Alibaba, PepsiCo, Disney, Palantir, McDonalds, Ford and more
- Arcus Biosciences: Did Gilead Sciences overpay for its latest investment?
- Gilead gets FDA okay for faster Yescarta production process
- Arcus shares extend gains amid mixed reactions on Gilead stake purchase
- Gilead invests $320M in Arcus, expands stake to 33%
- Big Pharma earnings season in spotlight amid positive sentiment
- PBMs ramp up lobbying efforts amid growing public scrutiny
- Gilead stands behind benefits of its CAR-T therapies
- CAR-T therapies to get boxed warning on blood cancer risk
- Gilead in selloff after late-stage setback for Trodelvy
- Biggest stock movers today: Boeing, NuStar Energy, Archer-Daniels-Midland, and more
- Gilead stock drops as Trodelvy fails Phase 3 lung cancer trial
- Eli Lilly’s Jaypirca to lead BTK inhibitor market for leukemia
- Arcus posts early-stage data for Gilead-partnered cancer therapy
- First RSV shots, groundbreaking gene therapy among 2024 drugs to watch
- Health stocks to watch this earnings season as sector poised for resurgence
- Gilead must face negligence claims over HIV drug development, court says
